Time to catch up briefly on one of everybody’s favorite drug companies, Valeant. Back in October, there was a lot of arguing going on about the company’s business model, and their apparent use of, well ... creative techniques to make sure that as many prescriptions as possible were filled for their portfolio of very pricy drugs. Throughout it all, Bill Ackman of the Pershing Square fund, a huge believer in (and investor in) Valeant, stood firm. The stock went on quite a wild ride, and Pershing Square’s position had some pretty bad moments, but they defending their investment (and Valeant in general) at great length.
Read Full Article »
